Teva knows that MNTA can make Copaxone. Teva's (desperate)Citizen Petitions should be encouraging to MNTA followers. The same problems they cite are the same problems MNTA faced in developing a generic Lovenox. Momenta was able to determine the exact components of the Lovenox and get approval. When Copaxone is off patent, I expect a quick release of the generic. It might be an over-simplification but If the court decision holds on the Lovenox case, any method to produce any generic will be OK as long as MNTA can prove it is an exact match. So the partial loss of Lovenox will be offset by the gain on Copaxone.
Market Data 
Markets 
AI
